Earnings PerformanceANIP reported earnings highlighted by a consensus beat on revenue and adj. EBITDA and an incremental raise to 2025 guidance.
Market ExpansionCortrophin Gel continues to grow well, taking market share from Acthar Gel and driving market expansion, including in label indications which Acthar does not have.
Product DevelopmentRoyalties from creto, which could be a blockbuster product in bladder cancer, are not yet reflected in ANIP's stock.